Merit Medical Systems Inc
Johnson & Johnson’s Interventional Solutions Business
JNJ’s Interventional Solutions segment generated third-quarter net revenues of $653.0 million, compared to $553.0 million in the third quarter of 2017.
What Analysts Recommend for Edwards Lifesciences
Of the 22 analysts covering Edwards Lifesciences in February 2018, 17 analysts have given the stock a “buy” or a higher rating.
Analyzing Edwards Lifesciences’ Recent Acquisitions
In December 2017, Edwards Lifesciences (EW) acquired Harpoon Medical for a total consideration of $119.5 million.
Exploring Merit Medical Systems’ Business Segments
In 3Q17, Merit Medical Systems’ cardiovascular segment generated revenues of $172.7 million—compared to $150.5 million in 3Q16.
Merit Medical Systems: Analysts’ Ratings in February 2018
Of the eight analysts covering Merit Medical Systems in February, four gave it a “strong buy,” three gave it a “buy,” and one gave it a “sell” rating.